Educational information, not medical advice — ask your doctor or midwife.
Simarouba glauca is a fast-growing tropical tree found across Central America, the Caribbean, parts of South America, and increasingly cultivated in India and Southeast Asia. Nearly every part of the tree — bark, leaves, roots, and seeds — has been used in traditional medicine, while its oil-rich seeds have drawn modern interest as a biofuel and edible oil source. It belongs to the Simaroubaceae family, a group well known for producing bitter compounds called quassinoids with documented biological activity.
The tree's most studied compounds are quassinoids — intensely bitter plant chemicals that disrupt the energy production and reproduction of parasites, harmful bacteria, and certain cancer cells. The seed oil is rich in oleic and lauric acids, which support healthy lipid profiles and have antimicrobial properties. Tannins and flavonoids in the leaves and bark add antioxidant and anti-inflammatory effects that help calm gut inflammation and support immune response.
Bark decoctions and tinctures are the most traditional forms for antiparasitic and fever-reducing use. Leaf extracts are used topically and internally for skin conditions and digestion. The cold-pressed seed oil can be used culinarily or applied to skin. Standardized capsules and powders are increasingly available, though quality and standardization vary widely.
Indigenous peoples of Central America and the Amazon have used Simarouba bark for centuries to treat malaria-like fevers, intestinal parasites, and digestive ailments. In India, it gained attention in the 20th century as a drought-resistant tree with dual value as a medicinal plant and biofuel crop, leading to significant Indian government interest in its cultivation. It also appears in traditional Brazilian and Caribbean herbal medicine under the name 'aceituno' or 'marupá'.
Evidence grades and traditional-use labels are explained in our methodology. Nothing here is medical advice.
Reviewed by the HealisticMD editorial team How we grade evidence →
The published evidence for Simarouba is weak or absent. That usually means no controlled trial has tested it, not that a trial found it ineffective — the two are different, and we grade only what has been published.
What it is typically used for, usual dose, cautions, and the study behind it where real trial data exists.
One email with the summary. We'll also send a short weekly evidence update — unsubscribe any time.